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Donor
Annulus
diameter [mm]
Valve/Frame
size [mm]
Pull force
towards
LV {N]
Pull force
towards
aorta [N]
Donor 1 33-36 F26 8.6 27
Donor 2 27-29 F29 461* 37.82*
Donor 3 21.5 V23 28 13
Donor 4 25-27 V23 12 3.8
Donor 5 21-23 V26 272* 272*
1* Suture broke due to excessive pull force
2* Stopped pulling at this force without any observed dislodgement.
Key: F – Frame,V- Valve N-Newtons
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comdifferences were observed in PPAR, post-procedural mean gradient, cerebrovascular
events, and 30-day or 1-year VARC-2 composite endpoints between the 2 groups.
Finally, at a median follow-up period of 429 days (IQR 208 - 730), Kaplan-Meier
curves reported no signiﬁcant differences in long-term all-cause (17.8% vs. 23%; Log
Rank p ¼ 0.210) and cardiovascular mortality (13.3% vs. 17.6%; Log Rank p ¼
0.256).
Conclusions: According to our results, direct MCV implantation is safe and effective,
with outcomes comparable to MCV implantation with PBAV. However it was
associated with a higher need of VBPD.
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Background: Transcatheter aortic valve implantation (TAVI) is an emerging treat-
ment option for inoperable or high risk patients. Low implantation (over 8mm) has
been frequently implicated with moderate or severe paravalvular aortic regurgitation
(PVR). However, it has not been evaluated the effect of high implantation on the
outcome of the procedure. The purpose of this study is to assess whether high im-
plantation affects the short- and long-term outcome of the procedure.
Methods: Consecutive patients who underwent TAVI were evaluated. Echocardio-
graphic parameters were recorded before the procedure, at discharge of the patient and
during one month- and one year- follow-up. Permanent pacemaker implantation (PPI),
one month- as well as one year- mortality were recorded according to VARC criteria.
ID was deﬁned as the distance both from the native coronary cusp (NCC) and the left
coronary cusp(LCC) to the deepest edge of the deployed bioprosthesis in the left
ventricle using an ofﬂine program. The patients were separated into two groups ac-
cording to the ID. Group I included all patients with normal (4-8 mm) or low im-
plantation (>8mm) and Group II included those with high (0-4 mm) or over the
annulus implantation(distance from either LCC or NCC < 0 mm).
Results: One hundrend eighty six consecutive patients (815.5 years, 103 males)
who underwent TAVI were recorded.In Group I, peak gradientat discharge (178 vs.
144 mmHg, p< 0.01) and mean gradient at discharge (94 vs. 7,53,5 ,p¼0.02)
was signiﬁcantly higher comparing to Group II, while there was no difference among
two groups during one month- and one year- follow up. Furthermore, the percentage
of patients with need for PPI after TAVI, was signiﬁcantly greater in Group I
comparing to Group II (45.6% vs. 2.9% , p¼0.03). Similarly, one year- all cause
mortality was higher in Group I (13,7% vs. 0%, p¼0.03) while one year- cardio-
vascular as well as one month- and in-hospital mortality did not differ among two
groups.
Conclusions: In conclusion, high implantation seems to have a positive effect on
short- and long-term outcome of the procedure.
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Background: Bicuspid aortic valve (BAV) is the most common congenital heart
disease and may lead to aortic valve stenosis. Although Transcatheter Aortic Valve
Replacement(TAVR) emerged as an alternative therapy in high-risk patients with
tricuspid aortic valve stenosis, presence of a stenotic BAV is often considered a
contraindication, due to its unique anatomy and increased risk of periprocedural
complications. We aimed to assess the feasibility and outcomes of TAVR in high-risk
patients with bicuspid aortic valve stenosis.
Methods: The study is a prospective, single-centre registry of patients with BAV
stenosis treated with TAVR. Periprocedural safety, hemodynamic and clinical
outcome was observed during patient follow-up.
Results: Of 130 high-risk patients with severe aortic stenosis who underwent
TAVR from January 2009 to May 2014 in our centre, 15 (12.5%) patients had
documented BAV. Patients were aged 769 years (range 56-90), with mean Lo-
gistic EuroScore I of 2011%, all in New York Heart Association functional class
III. The mean aortic valve area was 0.760.36 cm2, mean gradient was 45.315.1
mmHg and mean LVEF was 50.512.4%. The procedure was performed using
transfemoral access in 13 (87%), transaortic in 1 (6.5%) and transapical in 1
(6.5%) patient. Medtronic CoreValve prosthesis was implanted in 9 (60%) and
Edwards Sapien XT in 6 (40%) patients. TAVI procedure was successful in 13
patients (87%). Major adverse events according to the second Valvular AcademicB218 JACC Vol 64/11/Suppl B j SepResearch Consortium deﬁnitions were present in 2 patients: 1 periprocedural death
(Edwards Sapien XT 29) and 1 periprocedural stroke (Medtronic CoreValve 26).
Importantly, both complications were related to prosthesis dislocation from the
bicuspid aortic valve annulus. Postprocedural aortic valve mean gradient was 82
mmHg and AVA 1.40.4 cm2. After a mean follow-up of 1312 months (range
1-39) no further adverse events occurred. All survivors remained in NYHA class I
or II.
Conclusions: Our initial experience suggests TAVI using CoreValve and Sapien XT
prostheses in high risk patients with stenotic bicuspid aortic valve is feasible, leading
to good short term hemodynamic and clinical improvement.
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Background: TAVR success requires both anchoring and sealing in the native aortic
valve complex. These two processes may be unique and not interdependent. Using
undersized TAVR device we tested the mechanism of TAVR anchoring
Methods: Five cadaveric hearts with severe aortic stenosis were imaged with
CT-scanning. An annular diameter was measured, and a calcium score was assigned.
The hearts were pressurized such that SAPIEN 3 (Edwards Lifesciences) valves and
frames (implants) could be delivered and deployed. Two endoscopes were positioned,
one at the apex and the other in the ascending aorta, to enable visibility. Depending on
annulus size, an S3 valve or frame was chosen to be implanted under ﬂuoroscopic and
endoscopic guidance such that the implant would be smaller than the annulus
currently recommended per Edwards instructions for use (IFU), Strings were attached
at three points both at the inﬂow and outﬂow portions of the Edwards implants to pull
and measure the force required to move the prosthesis. The implants were deployed at
discrete inﬂation volume until the frame initially engaged with the native leaﬂets.
Dimensions were measured, and pull forces were applied in both the LV and aortic
directions until the implant demonstrated movement . A gauge attached to the strings,
measured dislodgement forces.
Results: See table
Conclusions: High pull forces are required to displace undersized TAVR valves in the
absence of annular interaction with the prosthesis indicating that: anchoring is at the
native leaﬂet level and that anchoring and sealing may be two distinct processes.TCT-747
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Background: Transcatheter aortic valve intervention (TAVI) is a recognized life-
saving treatment for those who are at high risk for conventional aortic valve surgery.
The ﬁnancial cost of a TAVI “pathway” from the time of referral to the time of
hospital discharge was assessed.
Methods: Consecutive patients (n¼46) who underwent TAVI between February
2012 and December 2013 at Hammersmith Hospital, London, UK were
included in this retrospective study. The analysis included costs of outpatient
appointment, investigations prior to the procedure, the TAVI procedure as well as
post-procedural costs including the cost of pacemaker implantation. NHS
tariff costs were used for the assessment. Comparison of the costs incurred
following implantation of the Edwards and CoreValve bioprostheses was also
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